AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17269558 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil concentrate (6 g/d, 4.4 g of LCn‐3PUFA)
Number of subjects: 17
Study 17269558 — intervention group
Group type: COMPARATOR
Intervention: Placebo (olive oil, 6 g/d)
Number of subjects: 17
Study 12927008 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (20 to 40 mg/day) after 1 week of placebo for 2 months
Number of subjects: 107
Study 12927008 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 107
Study 12927008 — intervention group
Group type: COMPARATOR
Intervention: Control group (ineffective treatment)
Number of subjects: 107
Study 10730039 — intervention group
Group type: EXPERIMENTAL
Intervention: Double phototherapy (conventional phototherapy with special blue light plus fiberoptic phototherapy)
Number of subjects: 0
Study 10730039 — intervention group
Group type: COMPARATOR
Intervention: Conventional phototherapy (special blue lamps alone)
Number of subjects: 0
Study 9042561 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis with low molecular weight heparins for 1 month
Number of subjects: 0
Study 9042561 — intervention group
Group type: COMPARATOR
Intervention: Conventional prophylaxis during hospitalisation
Number of subjects: 0
Study 1643938 — intervention group
Group type: EXPERIMENTAL
Intervention: Alexander technique (AT) instruction
Number of subjects: 10
Study 1643938 — intervention group
Group type: COMPARATOR
Intervention: Control group (no instruction)
Number of subjects: 10
Study 6397660 — intervention group
Group type: EXPERIMENTAL
Intervention: Semisynthetic human insulin (Actrapid HM, Novo)
Number of subjects: 12
Study 6397660 — intervention group
Group type: COMPARATOR
Intervention: Purified pork insulin (Actrapid MC, Novo)
Number of subjects: 12
Study 6397660 — intervention group
Group type: EXPERIMENTAL
Intervention: Both insulin preparations (HM and MC)
Number of subjects: 12
Study 31479068 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label placebo treatment for 3 weeks
Number of subjects: 127
Study 31479068 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 127
Study 30135248 — intervention group
Group type: EXPERIMENTAL
Intervention: hDPSC implantation
Number of subjects: 40
Study 30135248 — intervention group
Group type: COMPARATOR
Intervention: Apexification treatment
Number of subjects: 40
Study 26933897 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Carnitine 750 mg/day for 8 weeks
Number of subjects: 72
Study 26933897 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 72
Study 25062520 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group program
Number of subjects: 160
Study 25062520 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 160
Study 22433323 — intervention group
Group type: EXPERIMENTAL
Intervention: Twin-block appliance with Southend clasp
Number of subjects: 52
Study 22433323 — intervention group
Group type: COMPARATOR
Intervention: Twin-block appliance without Southend clasp
Number of subjects: 52
Study 19280298 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotiam (CTM)
Number of subjects: 100
Study 19280298 — intervention group
Group type: COMPARATOR
Intervention: Control (no antibiotic)
Number of subjects: 100
Study 17365993 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycaemic condition (plasma glucose = 15 mmol/L)
Number of subjects: 9
Study 17365993 — intervention group
Group type: COMPARATOR
Intervention: Euglycaemic condition (plasma glucose = 5 mmol/L)
Number of subjects: 9
Study 16377949 — intervention group
Group type: EXPERIMENTAL
Intervention: Etizolam (3.0 mg per day for 14 days)
Number of subjects: 53
Study 16377949 — intervention group
Group type: COMPARATOR
Intervention: Control group (no medical treatment)
Number of subjects: 53
Study 16377949 — intervention group
Group type: EXPERIMENTAL
Intervention: Low density of hematoma on CT
Number of subjects: 53
Study 16377949 — intervention group
Group type: EXPERIMENTAL
Intervention: Paresis as an initial symptom
Number of subjects: 53
Study 11970777 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived control
Number of subjects: 0
Study 11970777 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived difficulty
Number of subjects: 0
Study 11970777 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived control and perceived difficulty
Number of subjects: 0
Study 9813961 — intervention group
Group type: EXPERIMENTAL
Intervention: Transenvironmental programming (TP) + curriculum-based measurement (CBM)
Number of subjects: 0
Study 9813961 — intervention group
Group type: COMPARATOR
Intervention: Transenvironmental programming (TP)
Number of subjects: 0
Study 9813961 — intervention group
Group type: COMPARATOR
Intervention: Curriculum-based measurement (CBM)
Number of subjects: 0
Study 7906288 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine
Number of subjects: 0
Study 7906288 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated patients)
Number of subjects: 0
Study 2670188 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncology home care (OHC)
Number of subjects: 166
Study 2670188 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard home care (SHC)
Number of subjects: 166
Study 2670188 — intervention group
Group type: COMPARATOR
Intervention: Office care (OC)
Number of subjects: 166
Study 1071683 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrallazine
Number of subjects: 0
Study 1071683 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazoxide
Number of subjects: 0
Study 1071683 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroprusside
Number of subjects: 0
Study 1071683 — intervention group
Group type: EXPERIMENTAL
Intervention: Minoxidil
Number of subjects: 0
Study 31710842 — intervention group
Group type: EXPERIMENTAL
Intervention: AI screening tool for detecting low EF
Number of subjects: 20000
Study 31710842 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 20000
Study 30246408 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminiscence therapy applied once a week for 8 weeks, 60 minutes per session
Number of subjects: 60
Study 30246408 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study 28295134 — intervention group
Group type: EXPERIMENTAL
Intervention: REACH II
Number of subjects: 110
Study 28295134 — intervention group
Group type: EXPERIMENTAL
Intervention: REACH VA
Number of subjects: 110
Study 26265590 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Peer Support intervention
Number of subjects: 41
Study 26265590 — intervention group
Group type: COMPARATOR
Intervention: Standard intervention
Number of subjects: 41
Study 23331518 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine (GARDASIL)
Number of subjects: 1021
Study 23331518 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1021
Study 21173393 — intervention group
Group type: EXPERIMENTAL
Intervention: Training atypical examples in the category
Number of subjects: 6
Study 21173393 — intervention group
Group type: COMPARATOR
Intervention: Training typical examples
Number of subjects: 6
Study 18839054 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-PPS infusions (100-100 mg/day) for 5 days
Number of subjects: 89
Study 18839054 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline infusions)
Number of subjects: 89
Study 17719763 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium administered via pMDI and spacer
Number of subjects: 19
Study 17719763 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium administered via DPI (Rotahaler)
Number of subjects: 19
Study 17719763 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium (both pMDI and DPI)
Number of subjects: 19
Study 15386563 — intervention group
Group type: COMPARATOR
Intervention: Bolus mitoxantrone (MTZ)
Number of subjects: 40
Study 15386563 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion mitoxantrone (CI-MTZ)
Number of subjects: 40
Study 11350501 — intervention group
Group type: EXPERIMENTAL
Intervention: Enamel matrix proteins (EMD)
Number of subjects: 56
Study 11350501 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration (GTR)
Number of subjects: 56
Study 11350501 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of EMD and GTR
Number of subjects: 56
Study 11350501 — intervention group
Group type: COMPARATOR
Intervention: Flap surgery (control)
Number of subjects: 56
Study 9875045 — intervention group
Group type: EXPERIMENTAL
Intervention: High strength pancreatic enzyme preparations
Number of subjects: 86
Study 9875045 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 86
Study 7994797 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal androgen blockade (MAB) + epirubicin
Number of subjects: 0
Study 7994797 — intervention group
Group type: COMPARATOR
Intervention: Castration + epirubicin or estramustine
Number of subjects: 0
Study 7994797 — intervention group
Group type: COMPARATOR
Intervention: Medroxyprogesterone acetate (MPA) alone
Number of subjects: 0
Study 7994797 — intervention group
Group type: EXPERIMENTAL
Intervention: MPA + epirubicin
Number of subjects: 0
Study 2700237 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% solution of dimethylsulforoxide
Number of subjects: 0
Study 2700237 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapeutic methods (ultrasound and phonophoresis with analgin)
Number of subjects: 0
Study 911606 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric coated tablets (5 mg)
Number of subjects: 0
Study 911606 — intervention group
Group type: COMPARATOR
Intervention: Non-enteric coated tablets (5 mg)
Number of subjects: 0
Study 911606 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (10 mg)
Number of subjects: 0
Study 29100765 — intervention group
Group type: EXPERIMENTAL
Intervention: Transosseous tunnels that breached the anterior cortex (PA)
Number of subjects: 26
Study 29100765 — intervention group
Group type: EXPERIMENTAL
Intervention: Transosseous tunnels that did not breach the anterior cortex (TT)
Number of subjects: 26
Study 29100765 — intervention group
Group type: COMPARATOR
Intervention: Control group with unmodified patellas
Number of subjects: 26
Study 27403758 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic sacrocolpopexy
Number of subjects: 78
Study 27403758 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic sacrocolpopexy
Number of subjects: 78
Study 27403758 — intervention group
Group type: EXPERIMENTAL
Intervention: Both robotic and laparoscopic arms
Number of subjects: 78
Study 24332890 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20mg/day)
Number of subjects: 33
Study 24332890 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 22539587 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral octreotide 20 mg
Number of subjects: 75
Study 22539587 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous (sc) octreotide 100 μg
Number of subjects: 75
Study 19896902 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia
Number of subjects: 325
Study 19896902 — intervention group
Group type: COMPARATOR
Intervention: Normothermia
Number of subjects: 325
Study 17493510 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc + Oral Rehydration Solution (ORS)
Number of subjects: 117
Study 17493510 — intervention group
Group type: COMPARATOR
Intervention: Oral Rehydration Solution (ORS)
Number of subjects: 117
Study 16037113 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hyperstimulation cycles
Number of subjects: 171
Study 16037113 — intervention group
Group type: COMPARATOR
Intervention: Natural cycles
Number of subjects: 171
Study 12076842 — intervention group
Group type: EXPERIMENTAL
Intervention: LTG + PHT
Number of subjects: 156
Study 12076842 — intervention group
Group type: EXPERIMENTAL
Intervention: LTG + CBZ
Number of subjects: 156
Study 12076842 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of PHT
Number of subjects: 156
Study 12076842 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of CBZ
Number of subjects: 156
Study 10235613 — intervention group
Group type: EXPERIMENTAL
Intervention: ECP alone
Number of subjects: 15
Study 10235613 — intervention group
Group type: EXPERIMENTAL
Intervention: ECP + 3 MIU IFN‐alpha2a
Number of subjects: 15
Study 10235613 — intervention group
Group type: EXPERIMENTAL
Intervention: ECP + 6 MIU IFN‐alpha2a
Number of subjects: 15
Study 10235613 — intervention group
Group type: EXPERIMENTAL
Intervention: ECP + IFN‐alpha
Number of subjects: 15
Study 8728219 — intervention group
Group type: EXPERIMENTAL
Intervention: Swan neck coiled catheter
Number of subjects: 40
Study 8728219 — intervention group
Group type: COMPARATOR
Intervention: Straight Tenckhoff catheter
Number of subjects: 40
Study 8728219 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 2023770 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal baclofen infusion
Number of subjects: 9
Study 2023770 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 9
Study 2023770 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent programmable infusion pumps
Number of subjects: 9
Study 6178497 — intervention group
Group type: EXPERIMENTAL
Intervention: Different dose fractionation irradiation schedules
Number of subjects: 90
Study 6178497 — intervention group
Group type: COMPARATOR
Intervention: Administration of steroid or chemotherapy during the one‐month on‐study period
Number of subjects: 90
Study 28135215 — intervention group
Group type: EXPERIMENTAL
Intervention: Low RT volume (3 sets for each exercise, n = 10)
Number of subjects: 34
Study 28135215 — intervention group
Group type: EXPERIMENTAL
Intervention: High RT volume (6 sets for each exercise, n = 12)
Number of subjects: 34
Study 28135215 — intervention group
Group type: COMPARATOR
Intervention: Control (CT, n = 12)
Number of subjects: 34
Study 28135215 — intervention group
Group type: EXPERIMENTAL
Intervention: Low RT volume (3 sets)
Number of subjects: 34
Study 28135215 — intervention group
Group type: EXPERIMENTAL
Intervention: High RT volume (6 sets)
Number of subjects: 34
Study 28135215 — intervention group
Group type: COMPARATOR
Intervention: Control (CT)
Number of subjects: 34
Study 27689944 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment (0.67 mg/m2/day)
Number of subjects: 27
Study 27689944 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 27
Study 27689944 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 27
Study 27978848 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Lifestyles Programme (HeLP)
Number of subjects: 0
Study 27978848 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 25422193 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone and postal intervention
Number of subjects: 923
Study 25422193 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone intervention only
Number of subjects: 923
Study 25422193 — intervention group
Group type: EXPERIMENTAL
Intervention: Postal intervention only
Number of subjects: 923
Study 25422193 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 923
Study 22038464 — intervention group
Group type: EXPERIMENTAL
Intervention: CloA (750 mL/day, 802.5 mg polyphenols)
Number of subjects: 68
Study 22038464 — intervention group
Group type: COMPARATOR
Intervention: Control Beverage (CB, isocaloric equivalent to CloA, 750 mL/day)
Number of subjects: 68
Study 20482344 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthopedic maxillary expansion (OME)
Number of subjects: 30
Study 20482344 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgically assisted rapid palatal expansion (SARME)
Number of subjects: 30
Study 20482344 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 30
Study 16769180 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg oral THC (10 mg three times a day)
Number of subjects: 8
Study 16769180 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 mg oral THC (30 mg three times a day)
Number of subjects: 8
Study 16769180 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 16246942 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing sugar-free gum for half an hour after a refluxogenic meal
Number of subjects: 31
Study 16246942 — intervention group
Group type: COMPARATOR
Intervention: No chewing gum (control)
Number of subjects: 31
Study 11897207 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 1732
Study 11897207 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin 20 mg
Number of subjects: 1732
Study 11897207 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 1732
Study 11897207 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin 80 mg
Number of subjects: 1732
Study 11897207 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (both doses)
Number of subjects: 1732
Study 11897207 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 1732
Study 9471927 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 5 mg/d
Number of subjects: 447
Study 9471927 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 10 mg/d
Number of subjects: 447
Study 9471927 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 20/0 mg/d
Number of subjects: 447
Study 9471927 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 1 mg/d
Number of subjects: 447
Study 9471927 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 447
Study 7607932 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinamide 80 mg/kg/day
Number of subjects: 11
Study 7607932 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinamide 90 mg/kg/day
Number of subjects: 11
Study 7607932 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinamide 100 mg/kg/day
Number of subjects: 11
Study 7607932 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinamide (various doses)
Number of subjects: 11
Study 7607932 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinamide (increased doses)
Number of subjects: 11
Study 2369475 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine alone (group 1)
Number of subjects: 28
Study 2369475 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine vasopressin and epinephrine (group 2)
Number of subjects: 28
Study 7017496 — intervention group
Group type: EXPERIMENTAL
Intervention: Guacetisal (preparation B)
Number of subjects: 57
Study 7017496 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid (preparation A)
Number of subjects: 57
Study 7017496 — intervention group
Group type: COMPARATOR
Intervention: Guaiacol carbonate (preparation C)
Number of subjects: 57
Study 7017496 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromexine, acetylsalicylic acid, and codeine phosphate (preparation D)
Number of subjects: 57
Study 31720835 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib (LEN)
Number of subjects: 168
Study 31720835 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib (SOR)
Number of subjects: 168
Study 30901487 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 75 μg every third hour up to a maximum of four doses, then 75 μg twice daily until delirium free for 2 days, discharge, or a maximum of 7 days of treatment
Number of subjects: 20
Study 30901487 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 27925308 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium-nitride-oxide-coated stents
Number of subjects: 827
Study 27925308 — intervention group
Group type: COMPARATOR
Intervention: Everolimus-eluting stents
Number of subjects: 827
Study 27925308 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcified lesions
Number of subjects: 827
Study 27925308 — intervention group
Group type: COMPARATOR
Intervention: Non-calcified lesions
Number of subjects: 827
Study 27925308 — intervention group
Group type: EXPERIMENTAL
Intervention: Propensity-score matched subgroups
Number of subjects: 827
Study 25623393 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous golimumab 2 mg/kg plus methotrexate (MTX)
Number of subjects: 592
Study 25623393 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus methotrexate (MTX)
Number of subjects: 592
Study 25623393 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous golimumab plus methotrexate (MTX)
Number of subjects: 592
Study 23322512 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,25(OH)₂D in vitro
Number of subjects: 0
Study 23322512 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (7,000 IU daily)
Number of subjects: 0
Study 23322512 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21859318 — intervention group
Group type: EXPERIMENTAL
Intervention: Home whitening for two weeks with 16% carbamide peroxide in custom-made trays (Group A)
Number of subjects: 36
Study 21859318 — intervention group
Group type: EXPERIMENTAL
Intervention: Home whitening for two weeks with 16% carbamide peroxide in custom-made trays supplemented with in-office bleaching with 9% hydrogen peroxide (Group B)
Number of subjects: 36
Study 21859318 — intervention group
Group type: EXPERIMENTAL
Intervention: Home whitening for two weeks with 16% carbamide peroxide in custom-made trays supplemented with in-office bleaching with 27% hydrogen peroxide (Group C)
Number of subjects: 36
Study 21859318 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group A)
Number of subjects: 36
Study 19122356 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin (4 g/day)
Number of subjects: 102
Study 19122356 — intervention group
Group type: COMPARATOR
Intervention: Sulbactam/Ampicillin (6 g/day)
Number of subjects: 102
Study 21038666 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg/d
Number of subjects: 60
Study 21038666 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg/d
Number of subjects: 60
Study 21038666 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 16286164 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose laser
Number of subjects: 298
Study 16286164 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose laser
Number of subjects: 298
Study 16286164 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure (placebo)
Number of subjects: 298
Study 11991463 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonded amalgam restorations
Number of subjects: 137